MCID: MNN006
MIFTS: 42

Meninges Hemangiopericytoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Meninges Hemangiopericytoma

MalaCards integrated aliases for Meninges Hemangiopericytoma:

Name: Meninges Hemangiopericytoma 12 15
Hemangiopericytoma of Meninges 12 74
Meningeal Hemangiopericytoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4957
NCIt 51 C4660
UMLS 74 C0349622

Summaries for Meninges Hemangiopericytoma

MalaCards based summary : Meninges Hemangiopericytoma, also known as hemangiopericytoma of meninges, is related to hemangiopericytoma, malignant and mesenchymal chondrosarcoma. An important gene associated with Meninges Hemangiopericytoma is STAT6 (Signal Transducer And Activator Of Transcription 6), and among its related pathways/superpathways are PI3K-Akt signaling pathway and MAPK signaling pathway. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include brain, pineal and lung, and related phenotypes are Reduced mammosphere formation and cellular

Related Diseases for Meninges Hemangiopericytoma

Diseases related to Meninges Hemangiopericytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 hemangiopericytoma, malignant 31.1 IGF2 NAB2 STAT6 VIM
2 mesenchymal chondrosarcoma 30.4 HEY1 NCOA2 VIM
3 meningioma, familial 29.2 CD34 EPB41L3 GFAP IGF2 NAB2 STAT6
4 slipped capital femoral epiphysis 10.4 IGF1 IGFBP3
5 primitive neuroectodermal tumor of the cervix uteri 10.4 GFAP VIM
6 pseudopapilledema 10.4 IGF1 IGF2
7 parachordoma 10.3 GFAP VIM
8 rhabdoid meningioma 10.3 GFAP VIM
9 syringocystadenoma papilliferum 10.3 GFAP VIM
10 acid-labile subunit deficiency 10.3 IGF1 IGF2 IGFBP3
11 laron syndrome 10.3 IGF1 IGF2 IGFBP3
12 clear cell ependymoma 10.3 GFAP VIM
13 hypoglycemia 10.3
14 spindle cell rhabdomyosarcoma 10.3 GFAP NCOA2
15 type 1 diabetes mellitus 2 10.3 IGF2 INS
16 cerebral neuroblastoma 10.3 GFAP IGF2
17 hypoglycemic coma 10.3 IGF2 INS
18 silver-russell syndrome 10.3 IGF1 IGF2 IGFBP3
19 pineal region choriocarcinoma 10.3 CD34 IGF1
20 small intestine leiomyosarcoma 10.3 CD34 IGF2
21 diffuse idiopathic skeletal hyperostosis 10.3 IGF1 IGFBP3
22 glomangiomyoma 10.3 CD34 VIM
23 small intestinal sarcoma 10.3 CD34 IGF2
24 malignant pineal area germ cell neoplasm 10.3 CD34 IGF1
25 sternum cancer 10.3 CD34 VIM
26 deep leiomyoma 10.2 CD34 GFAP
27 sclerosing liposarcoma 10.2 CD34 STAT6
28 rubeosis iridis 10.2 IGF1 IGF2 INS
29 lymph node cancer 10.2 IGFBP3 PLAUR
30 pancreas disease 10.2 IGF1 IGF2 INS
31 primary hepatic neuroendocrine carcinoma 10.2 CHGA VIM
32 spinal meningioma 10.2
33 secretory meningioma 10.2
34 pediatric angiosarcoma 10.2 CD34 F8
35 ependymoblastoma 10.2 GFAP VIM
36 secondary adrenal insufficiency 10.2 IGF1 IGFBP3 INS
37 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.2 IGF1 IGFBP3 INS
38 hyperpituitarism 10.2 IGF1 IGFBP3 INS
39 meningioma, radiation-induced 10.2 EPB41L3 GFAP VIM
40 hobnail hemangioma 10.2 CD34 F8
41 leiomyoma 10.2 CD34 IGF2 VIM
42 hypopituitarism 10.1 IGF1 IGFBP3 INS
43 myxopapillary ependymoma 10.1 GFAP VIM
44 kaposiform hemangioendothelioma 10.1 CD34 PECAM1
45 cellular ependymoma 10.1 CHGA GFAP
46 spleen cancer 10.1 CD34 F8
47 plexiform schwannoma 10.1 CD34 GFAP
48 hyperinsulinism 10.1 IGF1 IGFBP3 INS
49 fetal macrosomia 10.1 IGF1 IGF2 IGFBP3 INS
50 acromegaly 10.1 IGF1 IGF2 IGFBP3 INS

Graphical network of the top 20 diseases related to Meninges Hemangiopericytoma:



Diseases related to Meninges Hemangiopericytoma

Symptoms & Phenotypes for Meninges Hemangiopericytoma

GenomeRNAi Phenotypes related to Meninges Hemangiopericytoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 CD34 CHGA CSF1R HEY1 IGF1 IGF2

MGI Mouse Phenotypes related to Meninges Hemangiopericytoma:

47 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.48 CACNA1A CD34 CSF1R EPB41L3 GFAP HEY1
2 homeostasis/metabolism MP:0005376 10.42 CACNA1A CD34 CHGA CSF1R F8 GFAP
3 growth/size/body region MP:0005378 10.4 CACNA1A CHGA CSF1R GFAP HEY1 IGF1
4 behavior/neurological MP:0005386 10.38 CACNA1A CSF1R EPB41L3 GFAP IGF2 IGFBP3
5 immune system MP:0005387 10.32 CACNA1A CD34 CSF1R F8 GFAP IGF1
6 hematopoietic system MP:0005397 10.29 CACNA1A CD34 CSF1R F8 IGF1 IGF2
7 endocrine/exocrine gland MP:0005379 10.28 CACNA1A CHGA CSF1R EPB41L3 IGF1 IGF2
8 mortality/aging MP:0010768 10.28 CACNA1A CHGA CSF1R EPB41L3 F8 GFAP
9 cardiovascular system MP:0005385 10.26 CHGA GFAP HEY1 IGF1 IGF2 INS
10 nervous system MP:0003631 10.2 CACNA1A CHGA CSF1R EPB41L3 GFAP HEY1
11 integument MP:0010771 10.16 CACNA1A CD34 CSF1R IGF1 IGF2 IGFBP3
12 muscle MP:0005369 10.15 CACNA1A CHGA GFAP HEY1 IGF1 IGF2
13 liver/biliary system MP:0005370 9.98 IGF2 IGFBP3 INS NAB2 PECAM1 PLAUR
14 normal MP:0002873 9.91 CACNA1A CSF1R EPB41L3 GFAP HEY1 IGF1
15 reproductive system MP:0005389 9.77 CACNA1A CHGA CSF1R EPB41L3 F8 IGF1
16 renal/urinary system MP:0005367 9.7 CHGA IGF1 IGF2 INS PECAM1 PLAUR
17 respiratory system MP:0005388 9.28 CACNA1A IGF1 IGF2 NAB2 PECAM1 PLAUR

Drugs & Therapeutics for Meninges Hemangiopericytoma

Drugs for Meninges Hemangiopericytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
6
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
8
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
9
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
10
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
11
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
12
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
13
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
14
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
15 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
21
Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
22 Narcotics Phase 3
23 Adjuvants, Anesthesia Phase 3
24 Analgesics Phase 3,Phase 1
25 Anesthetics, Intravenous Phase 3
26 Liver Extracts Phase 3,Phase 1
27 Anesthetics, General Phase 3
28 Anesthetics Phase 3
29 Analgesics, Opioid Phase 3
30 Central Nervous System Depressants Phase 3
31 Peripheral Nervous System Agents Phase 3,Phase 1
32 Cola Phase 3,Phase 1
33 Cholinesterase Inhibitors Phase 3,Phase 2
34 Neurotransmitter Agents Phase 3,Phase 2
35 Nootropic Agents Phase 3,Phase 2
36 Cholinergic Agents Phase 3,Phase 2
37 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
38 Immunologic Factors Phase 3,Phase 2,Phase 1
39 Etoposide phosphate Phase 3,Phase 2
40 Antirheumatic Agents Phase 3,Phase 2,Phase 1
41 Antimitotic Agents Phase 3,Phase 2,Phase 1
42 Anti-Infective Agents Phase 3,Phase 2,Phase 1
43 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
45
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
46
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
47
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
48
Bevacizumab Approved, Investigational Phase 2 216974-75-3
49
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
50
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Completed NCT00423618 Phase 3
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
11 Proton Radiation For Meningiomas and Hemangiopericytomas Unknown status NCT01117844 Phase 1, Phase 2
12 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
13 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
14 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
15 Imatinib Mesylate in Treating Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
16 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
17 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
18 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
19 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
20 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
21 Vatalanib in Treating Patients With Recurrent or Progressive Meningioma Completed NCT00348790 Phase 2 vatalanib
22 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
23 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
24 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
25 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
26 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
27 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
28 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
29 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
30 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2 gefitinib
31 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
32 A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
33 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
34 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
35 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Active, not recruiting NCT02815995 Phase 2 Durvalumab;Tremelimumab
36 S9624 Ifosfamide in Treating Patients With Meningeal Tumors Terminated NCT00003292 Phase 2 ifosfamide
37 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
38 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
39 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Completed NCT01082926 Phase 1
40 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
41 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
42 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib
43 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
44 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
45 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
46 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
47 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
48 CC-5013 in Treating Patients With Recurrent Glioma Completed NCT00036894 Phase 1 lenalidomide
49 Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
50 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat

Search NIH Clinical Center for Meninges Hemangiopericytoma

Genetic Tests for Meninges Hemangiopericytoma

Anatomical Context for Meninges Hemangiopericytoma

MalaCards organs/tissues related to Meninges Hemangiopericytoma:

42
Brain, Pineal, Lung, Liver, Bone, Testes, Small Intestine

Publications for Meninges Hemangiopericytoma

Articles related to Meninges Hemangiopericytoma:

# Title Authors Year
1
Hemangiopericytoma of meninges--a "malignant" challenge. ( 24631649 )
2015
2
Hemangiopericytoma of meninges. I. Histopathological variability and differential diagnosis. ( 3811681 )
1986
3
Hemangiopericytoma of meninges. II. General and clinical data. ( 3811682 )
1986

Variations for Meninges Hemangiopericytoma

Expression for Meninges Hemangiopericytoma

Search GEO for disease gene expression data for Meninges Hemangiopericytoma.

Pathways for Meninges Hemangiopericytoma

GO Terms for Meninges Hemangiopericytoma

Cellular components related to Meninges Hemangiopericytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.56 F8 IGFBP3 INS PLAUR
2 platelet alpha granule lumen GO:0031093 9.33 F8 IGF1 IGF2
3 insulin-like growth factor ternary complex GO:0042567 8.96 IGF1 IGFBP3
4 insulin-like growth factor binding protein complex GO:0016942 8.62 IGF1 IGFBP3

Biological processes related to Meninges Hemangiopericytoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.76 IGF1 IGF2 IGFBP3 INS
2 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 CSF1R IGF1 PECAM1
3 platelet degranulation GO:0002576 9.56 F8 IGF1 IGF2 PECAM1
4 intermediate filament organization GO:0045109 9.55 GFAP VIM
5 astrocyte development GO:0014002 9.54 GFAP VIM
6 positive regulation of insulin receptor signaling pathway GO:0046628 9.52 IGF2 INS
7 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.51 IGF1 IGFBP3
8 positive regulation of glucose import GO:0046326 9.5 IGF1 INS TERT
9 negative regulation of blood vessel diameter GO:0097756 9.49 CHGA INS
10 Bergmann glial cell differentiation GO:0060020 9.43 GFAP VIM
11 glomerular endothelium development GO:0072011 9.4 CD34 PECAM1
12 intermediate filament-based process GO:0045103 9.37 GFAP VIM
13 positive regulation of mitotic nuclear division GO:0045840 9.33 IGF1 IGF2 INS
14 positive regulation of glycogen biosynthetic process GO:0045725 9.13 IGF1 IGF2 INS
15 positive regulation of MAPK cascade GO:0043410 9.02 CSF1R IGF1 IGF2 IGFBP3 INS

Molecular functions related to Meninges Hemangiopericytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 IGF1 IGF2 INS
2 structural constituent of cytoskeleton GO:0005200 9.43 EPB41L3 GFAP VIM
3 insulin receptor binding GO:0005158 9.13 IGF1 IGF2 INS
4 insulin-like growth factor receptor binding GO:0005159 8.8 IGF1 IGF2 INS
5 protein binding GO:0005515 10.11 CACNA1A CSF1R EPB41L3 F8 GFAP HEY1

Sources for Meninges Hemangiopericytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....